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I-49 Strategy for recalcitrant MRSA infections An
evolving clinical challenge
P.R. Hsueh*. Divisions of Clinical Microbiology and
Infectious Diseases, Departments of Laboratory Medicine
and Internal Medicine, National Taiwan University Hospital,
National Taiwan University College of Medicine, Taipei,
Taiwan
Glycopeptides (vancomycin and teicoplanin) represent the
gold standard for therapy of invasive infections caused
by multidrug-resistant Staphylococcus aureus, most notably
hospital-acquired methicillin-resistant S. aureus (MRSA).
Reports of increasing in vitro resistance to glycopeptides
combined with reports of clinical failures underscore the
need for alternative therapies. Older agents with favorable
in vitro potency available in oral and/or intravenous
forms include trimethoprim-sulfamethoxazole, rifampin,
fusidic acid, fosfomycin, and clindamycin. However, limited
clinical data exist to support their routine use as initial
therapy in the treatment of invasive disease. Newer
treatment options for MRSA include linezolid, quinupristin-
dalfopristin, daptomycin, cftobiprole, tigecycline, and
nemonoxacin. With the exception of linezolid, these newer
agents require intravenous administration. Combination
therapy is mandatory for selected invasive diseases
refractory to standard monotherapies. These diseases
include endocarditis, meningitis, septic arthritis, prosthetic
device infections, and other recalcitrant MRSA Infections.
Some novel agents are under investigation, consisting
of oritavancin, dalbavancin, telavancin, and ceftobiprole.
Daptomycin is a promising antibiotic for the treatment of
patients with right-sided endocarditis and bacteraemia.
However, development of hematogenous spread of MRSA
resulting in multiple lung abscesses during daptomycin
treatment for bacteremia and right-sided endocarditis
and treatment failure for infective endocarditis due
to daptomycin-nonsusceptible MRSA have been reported.
Routinely tests of the daptomycin susceptibility is necessary
before the use as a rescue therapy for persistent
MRSA infection and difﬁcult-to-eradicate infectious foci
especially after a prolonged glycopeptide therapy. To
prevent prolonged glyopeptide therapy, using the maximum
tolerated dose of glycopeptide and aggressive adjnctive
therapies such as surgical interventions to remove culprit
foci are the best strategy for the treatment of recalcitrant
MRSA infections.
Concurrent Session 9 End-Stage Liver Diseases
and Complications
I-50 Cirrhotic cardiomyopathy: an unappreciated
complication of endstage liver disease
S.S. Lee*. Liver Unit, University of Calgary, Calgary,
Canada
In patients and animal models with cirrhosis, the
heart is abnormal. Although the circulation becomes
hyperdynamic, manifested as increased cardiac output
and decreased peripheral vascular resistance and
arterial pressure, the heart responds subnormally to
numerous stimuli/stresses. Cardiac ventricular function
under physiological, pharmacological or surgical stress
is blunted, with abnormalites of both systolic and
diastolic function. This condition is known as cirrhotic
cardiomyopathy. Other features of the syndrome include:
(a) electrophysiological changes in repolarization including
prolonged electrocardiographic QT interval and a curious
dissynchrony in the normally tightly-regulated time interval
between electrical and mechanical onset of systole,
(b) enlargement or hypertrophy of cardiac chambers,
(c) markers of cardiac ‘distress’ such as BNP or pro-BNP
and troponin I.
Although these changes when initially described almost
4 decades ago were ascribed to a mild or latent form
of alcoholic cardiotoxicity, it is now incontrovertibly
established that the condition of cirrhosis per se is
associated with this, as patients and animal models
with non-alcoholic cirrhosis show the same pattern
or cardiac dysfunction. Recent evidence implicates a
signiﬁcant pathogenic role of this syndrome in the
development of acute hepatorenal syndrome after
spontaneous bacterial peritonitis and poor outcomes such
as increased mortality/morbidity after challenges such as
TIPS insertion and liver transplantation. It may also explain
the uncommon but mysterious and inexplicable onset of
heart failure in the peri- and post-transplantation period
in patients with no previous history of heart disease or
dysfunction.
Several pathogenic mechanisms have been described
including: dysfunction or defects in the cardiac b-adrenergic
receptor system, plasma membrane physico-chemical milieu
(decreased membrane biophysical ﬂuidity due to an
increased cholesterol:phospholipid ratio in the plasma
membrane lipid bilayer), membrane calcium channels, and
humoral factors such as cytokines, nitric oxide, carbon
monoxide and endogenous cannabinoids. Many of these
pathogenic mechanisms are inter-related and their exact
relationship is the subject of ongoing research.
Treatment strategies for cirrhotic cardiomyopathy remain
unclear. Fortunately over heart failure is distinctly
uncommon. Repolarization abnormalities such as QT
prolongation may respond to b-blockade. Promising avenues
of inquiry include cardiac anti-ﬁbrogenic therapies such
as angiotensin converting enzyme inhibitors. Cirrhotic
cardiomyopathy is a previously underappreciated syndrome
with important clinical consequences in patients with
cirrhosis, especially given the emergence of liver
transplantation as effective therapy for endstage liver
disease.
I-51 Infectious complications in acute liver failure
V. Bhatia *. Institute of Liver and Biliary Sciences (ILBS),
Delhi, India
Infection and cerebral edema are the two most common
fatal complications of acute liver failure (ALF). ALF is a
state of immunosuppression. In addition there are frequent
breaches of the skin and mucus membrane barriers, and
need for invasive treatments and monitoring. Development
of infection at any site during grade I or II encephalopathy
(HE) is an independent risk factor for worsening of HE grade.
In addition, infection can directly aggravate liver damage,
and increases mortality in ALF.
Clinical signs such as high temperature and leukocyte
count may be absent in 30% of ALF patients, and
daily microbiological surveillance is recommended. An 80%
infection rate has been reported from the west. Over
70% of the isolates in the west, were Gram-positive
organisms. In our center, the infection rate of ALF patients
is around 60% and 80% of our isolates are Gram-negative.
The most common isolates are Acinetobacter baumanni,
Klebsiella pneumonia, Escherichia coli, and Pseudomonas
aeruginosa. We found that 94.7% Gram-negative isolates
were ESBL positive, and 66.7% Gram-positive isolates
were Methicillin resistant. In addition we had a 12.5%
fungemia rate with Aspergillus spp. and tropicalis and
glabrata species of Candida being the most common
isolates. Western series have reported fungemia rates of
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32% in ALF patients. All patients with fungal infection had
concomitant bacterial infections. Deterioration in HE after
initial improvement, unresponsive pyrexia, renal failure,
and a high leukocyte count despite antibiotics, were clinical
clues to an underlying fungal infection.
The most common site of infection in our patients was the
respiratory tract. Since two-thirds of all deaths occur within
ﬁrst 72 hours and the median time to positive cultures was
4.5 days in our patients, we advocate prophylactic systemic
antibiotics in all ALF patients at admission according to
local sensitivity patterns. Enteral decontamination regimes
need not be added to systemic antibiotics. Improvement
in neutrophil phagocytosis and killing has been shown
both in-vitro and in-vivo by G-CSF. Recently ammonia has
been shown to directly inhibit neutrophil function in vivo,
and ammonia lowering treatments in ALF are a promising
strategy for the future.
I-52 TIPS (transjugular intrahepatic portosystemic
shunts) in the treatment of complications of portal
hypertension
D.M. Brooks *. Austin Hospital, Heidelberg, Australia
Chronic liver disease and its complications are common
throughout the world. Signiﬁcant regional variation exists,
but hepatitis B and C and alcohol abuse account for
around 90% of cases. Autoimmune chronic active hepatitis,
primary and secondary biliary cirrhosis, hemochromatosis,
Budd Chiari syndrome and other rare conditions make up
the remaining 10%. Risk of death comes from variceal
bleeding, progressive liver failure and hepatoma. Among
the important quality of life issues are management of
ascites and hepatic encephalopathy.
Ideally these patients are treated with liver transplantation
however for many patients this treatment is unsuitable or
unavailable. TIPS can be used to control the complications of
portal hypertension in this group. For best patient outcome
TIPS needs to be combined with best medical management
as part of a multidisciplinary approach. Patient selection
and timing of TIPS are critical to a good clinical outcome.
While TIPS has been available since 1985 its clinical
effectiveness was initially limited by a high rate of shunt
stenosis and occlusion. The introduction of covered TIPS
endoprostheses has signiﬁcantly improved the long term
patency and clinical effectiveness of this procedure.
Concurrent Session 10 Management of
Hepatitis C
I-53 Treatment of chronic hepatitis C in Taiwan
J.H. Kao*. Hepatitis Research Center, Graduate Institute
of Clinical Medicine and Department of Internal Medicine,
National Taiwan University College of Medicine and
National Taiwan University Hospital, Taipei, Taiwan
Chronic hepatitis C virus (HCV) infection is a major
health problem worldwide because of its potential adverse
sequelae including cirrhosis-related complications and
hepatocellular carcinoma (HCC). Taiwan is a country
endemic for HCV infection, and 30% of Taiwanese patients
with chronic liver diseases are attributable to this virus.
The primary goal of treatment for chronic hepatitis C is to
eliminate HCV replication and therefore reduce or prevent
hepatic injury. Furthermore, the ultimate long-term goal of
therapy is to prevent hepatic decompensation, to reduce or
prevent disease progression to cirrhosis and/or HCC, and to
prolong survival of patients.
In Taiwan, interferon (IFN)-based therapy has long been
used to treat chronic hepatitis C. Our earlier pilot study
showed that naive patients with 3 MU of conventional IFN
thrice weekly plus 1,200mg of oral ribavirin daily for 24
weeks had a signiﬁcantly higher sustained virologic response
(SVR) rate than those with no treatment (43% vs. 6%). A
randomized trial also suggested that more than one-third
Taiwanese chronic hepatitis C patients who failed prior
IFN monotherapy could achieve SVR after 24 weeks of re-
treatment with combination therapy, and the response rate
was even higher (53%) in those with IFN 6 MU. A study
from southern Taiwan also conﬁrmed that 6 MU regimen
has better efﬁcacy than 3 MU regimen in terms of virologic
and histological responses. In addition, sustained virologic
response to interferon-based therapy can result in reducing
HCC incidence and improving patient survival. Similar to
Caucasian patients with chronic hepatitis C, a recent
multicenter randomized study in Taiwan has conﬁrmed that
combination of PEG-IFN and ribavirin therapy for 24 weeks
had signiﬁcantly better SVR and lower relapse rate when
compared to IFN and ribavirin therapy in our genotype 1
chronic hepatitis C patient, whereas both regimens can be
recommended for genotype non-1 patients. Although the
recommended treatment for genotype patients is peg-IFN
plus ribavirin for 48 weeks, whether treatment duration of
24 weeks is as effective as standard treatment in genotype 1
patients with a rapid virological response (RVR; seronegative
for HCV RNA at 4 weeks) remains unclear. Two large-scale
randomized trials in Taiwan all showed that genotype 1
patients derive a signiﬁcantly better SVR from 48 weeks
versus 24 weeks of peginterferon/ribavirin even if they
attain an RVR. Both 24 and 48 weeks of therapy can achieve
high SVR rates in genotype 1 patients with low viral loads
and an RVR. In addition, a randomized study showed that
16 weeks and 24 weeks of peg-IFN treatment with weight-
based ribavirin at a dose of 1000 1200mg/day provided
equal efﬁcacy in genotype 2 patients who achieved rapid
virologic response (RVR) at 4 weeks.
Several speciﬁcally targeted antiviral therapies for
hepatitis C (STAT-C) have been designed to directly inhibit
the replication of HCV, and early preclinical data showed
encouraging results. Therefore, combination therapy with a
backbone of peg-IFN plus ribavirin, or perhaps using several
of these small molecules with distinct modes of action and
resistance proﬁles, will be proven useful in the future.
I-54 Optimizing HCV antiviral treatment: reducing
treatment duration
S.S. Lee*. Liver Unit, Faculty of Medicine, University of
Calgary, Calgary, Canada
The current ‘gold standard’ treatment for patients with
chronic hepatitis C consists of pegylated interferon-alfa
(PEG-IFN) + ribavirin, for a duration of 48 weeks for those
with HCV genotype 1 and 4, and 24 weeks for genotypes
2 and 3. However, these rigid treatment durations are
now being questioned in light of new information on viral
kinetic responses during the early phase of treatment.
In particular, those with a rapid viral response (RVR),
deﬁned as undetectability of HCV-RNA at 4wk after onset of
treatment, may only need a shorter duration of treatment
whether they have genotype 1, 2, or 3. Evidence suggesting
a shorter 24-wk course in genotype 1 RVR patients and
12 16 weeks in those with genoytpes 2/3 will be presented.
Although there are several pre-treatment baseline factors
that may predict sustained virological response (SVR), such
as genotype, viral load, presence of advanced ﬁbrosis, body
weight and ethnicity, one of the strongest predictors of SVR
is the presence of RVR. Regardless of genotype (studied
only for genotypes 1, 2, 3), the presence of RVR appears
